Halozyme CEO Helen Torley

Roche's Chugai lines up a $185M deal to switch drug can­di­date to sub­cu­ta­neous for­mu­la­tion

Back in the spring of 2020, J&J and its part­ner on the big mul­ti­ple myelo­ma drug Darza­lex an­nounced a big im­prove­ment for the pro­gram af­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.